Top Levofloxacin Brands: Your Guide to Quality and Trust

Levofloxacin, a widely prescribed antibiotic, is available from several reputable pharmaceutical brands across the globe. Choosing the best brand depends on factors like availability, price, and the specific healthcare requirements of the patient. Some of the leading brands are known for their stringent quality control and reliable efficacy. To explore a detailed list of the top levofloxacin brands and their benefits, please see the information below.

Illustration of levofloxacin

Best brands of levofloxacin in 2025

Levaquin

Levaquin, formerly a brand name of levofloxacin by Janssen Pharmaceuticals, was a prominent fluoroquinolone antibiotic used to treat various bacterial infections, including pneumonia, skin infections, and urinary tract infections. Although the Levaquin brand has been discontinued in the U.S., generic versions of levofloxacin continue to be widely used. The global levofloxacin market, which includes these generics, is expected to grow at a CAGR of 5.3% from 2024 to 2033, reaching $2.17 billion by 2028. This growth is driven by factors such as an aging population, increased incidence of respiratory and urinary tract infections, and the global challenge of antibiotic resistance. The market is segmented into 250 mg, 500 mg, and 750 mg tablets, distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tavanic

Tavanic, a brand of levofloxacin produced by Sanofi-Aventis, is a leading synthetic antibacterial agent of the fluoroquinolone class, approved in the EU since 1997 and available in various strengths including 250 mg and 500 mg film-coated tablets, as well as a 5 mg/ml solution for infusion. It is indicated for treating infections such as acute bacterial sinusitis, community-acquired pneumonia, and complicated skin and soft tissue infections. The market for levofloxacin, including Tavanic, is expected to grow at a CAGR of 5.3% from 2024 to 2033, driven by factors like the increasing incidence of respiratory infections and urinary tract infections. Tavanic is widely used across multiple EU member states and other regions, contributing significantly to the global levofloxacin market size, which is projected to reach $2.17 billion by 2033. The product's broad in vitro antibacterial spectrum, including effectiveness against Gram-positive organisms like Streptococcus pneumoniae, further solidifies its position in the market. For more detailed information, you can refer to the EU Community Register document.

Levox

Levofloxacin, particularly under the brand name Levaquin by Johnson & Johnson but also produced by other companies like Lupin Pharmaceuticals, is a highly effective antibiotic. Lupin Pharmaceuticals, although initially faced challenges in entering the US market due to patent disputes in 2010, has since become a significant player in the global levofloxacin market. The global levofloxacin market, which includes Lupin's products, is projected to grow at a CAGR of 5.3% from 2024 to 2033, reaching $2.17 billion by 2033. North America, where Lupin operates, accounts for the largest market share, approximately 44% of the revenue. The market growth is driven by increasing cases of bacterial infections and the aging population.

Factive

Factive, a brand of levofloxacin produced by Cornerstone Therapeutics, is renowned for its efficacy in treating various bacterial infections. Levofloxacin, a fluoroquinolone antibiotic, has been shown to achieve high bioavailability, with oral absorption rates exceeding 99%. It is effective against a broad spectrum of pathogens, including both Gram-positive and Gram-negative bacteria. In clinical studies, levofloxacin has demonstrated success rates of up to 90% in treating respiratory tract infections and other bacterial diseases. The drug is typically administered once daily, with a half-life of approximately 6-8 hours, allowing for convenient dosing regimens.

Glevo

Glenmark Pharmaceuticals, under its brand, is one of the leading producers of levofloxacin, a broad-spectrum antibiotic. The company is part of a consolidated market that includes other key players like Lupin Limited, Dr. Reddy's Laboratories Ltd., and Zydus Cadila. Glenmark's involvement in new product development, mergers and acquisitions, and geographical expansion has contributed significantly to the growth of the levofloxacin market, which is expected to reach $2.17 billion by 2033 with a CAGR of 5.3% from 2024 to 2033. The rising incidence of bacterial infections, such as tuberculosis with 10.6 million cases globally in 2021, drives the demand for levofloxacin. Glenmark's products are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. For more detailed information, visit Glenmark Pharmaceuticals' official website.

Levoday

Levoday 500mg Tablet, produced by Aristo Pharmaceuticals, is a highly effective antibiotic belonging to the fluoroquinolone class, specifically levofloxacin. It is widely used to treat various bacterial infections, including acute sinusitis, pneumonia, urinary tract infections, and skin and soft tissue infections. With a high bioavailability of 99%, Levoday ensures efficient absorption and action against bacterial enzymes like DNA gyrase, crucial for bacterial DNA synthesis. The medication has been prescribed extensively, with over 23 million outpatient prescriptions for fluoroquinolones, including levofloxacin, reported in 2011. It is essential to follow the prescribed dose and duration to avoid side effects and ensure the full eradication of the infection. For more information about Levoday 500mg Tablet, visit this online pharmacy listing.

L-Champ

Levofloxacin, particularly under the brand L-Champ by Unichem Laboratories, is recognized for its high quality and efficacy in treating various bacterial infections. Unichem Laboratories, an integrated pharmaceutical company, has a strong presence in the domestic formulations segment and has been a reliable producer of levofloxacin since its approval in 1996. The market for levofloxacin is expected to grow at a CAGR of 5.3% from 2024 to 2033, driven by increasing demand for antibiotics and rising cases of respiratory and urinary tract infections. L-Champ is part of this growing market, contributing to the global levofloxacin market size projected to reach $2.17 billion by 2033. Unichem Laboratories' commitment to quality and safety has made L-Champ a trusted choice among healthcare providers.

Moxiflox

Moxifloxacin, produced by companies like those affiliated with Sun Pharmaceutical Industries, is recognized for its efficacy and safety profile, particularly in treating multidrug-resistant tuberculosis (MDR-TB). Studies have shown that moxifloxacin regimens have a significantly elevated treatment success rate compared to levofloxacin or conventional therapy, with an odds ratio of 1.94 (95% CI 1.16-3.25, P = .01). It has a broad spectrum of antibacterial activity against both gram-positive and gram-negative bacteria and is known for its good pharmacokinetic profile, including a serum half-life of 10-12 hours. Moxifloxacin also exhibits a satisfactory safety profile with no significant increase in risks of gastrointestinal trouble, hepatotoxicity, or dermatologic abnormalities compared to levofloxacin. Sun Pharmaceutical Industries, one of the largest generic pharmaceutical companies, ensures high-quality and affordable medicines through its extensive manufacturing network.

Zymar

Zymar, produced by Allergan, is a highly effective ophthalmic solution containing gatifloxacin 0.3%, approved for treating bacterial conjunctivitis. It stands out due to its dual mechanism of action, attributed to its 8-methoxy group, and its rapid bacterial reduction, with studies showing a 99.9% reduction in Staphylococcus species cultures in just 15 minutes. Zymar is preserved with benzalkonium chloride (BAK) 0.005%, which may provide additional antimicrobial benefits. The drug has been shown to penetrate well into ocular tissues, ensuring adequate concentrations to kill organisms effectively. Despite some formulation differences, Zymar is often preferred for its efficacy and patient comfort. For more information, you can visit their official product page.

Zoxan

Zoxan, a brand of levofloxacin produced by Ranbaxy Laboratories, is a prominent player in the global levofloxacin market, known for its widespread availability in over 120 countries through licensing agreements. The brand has benefited from the transfer of marketing rights from Sanofi-Aventis, enhancing its reach in regions like Romania and South Africa. With a strong presence, Zoxan contributes significantly to the market growth, which is expected to achieve a CAGR of 5.3% from 2024 to 2033. The North American market, where Zoxan is well-established, accounts for a major share of 44% in terms of revenue. This robust market presence underscores Zoxan's position as one of the best producers of levofloxacin. For more detailed information, visit their press release.